The impact of COVID-19 is reaching far beyond the direct consequences of SARS-CoV-2 infection. The wholesale repurposing of resources to tackle the pandemic has left little room for ongoing efforts to control other infectious diseases---eg, HIV, malaria, and tuberculosis. Particularly concerning is the impact this shift in resource allocation is having on tuberculosis, with its unenviable status as the infectious disease responsible for the most deaths worldwide each year. Adding to this concern is the progression of the COVID-19 pandemic to nations with large burdens of tuberculosis, where changes in the response to tuberculosis will be most keenly felt.

In a News piece in this issue, Priya Venkatesan outlines the effect the response to COVID-19 is having on diagnostics for other infections. It is feared that redirecting diagnostic capacity entirely towards the detection of SARS-CoV-2 will hinder efforts and undo progress in controlling other infectious diseases. Compounding the risks of shifting diagnostic resources is the move by diagnostics manufacturers to largely produce SARS-CoV-2 tests. So even if the capacity was available to support ongoing tuberculosis testing, for example, these efforts might still be restricted by a lack of equipment.

The research Articles in this issue redirect our focus onto works that explore many facets of tuberculosis. Shannon Duffy and colleagues assess zoonotic tuberculosis and find that *Mycobacterium bovis* might be an inadequate proxy. Jean Claude Semuto Ngabonziza and colleagues look at false-positive rifampicin-resistant Xpert MTB/RIF results and the need for a more robust approach before moving to treatment of multidrug-resistant disease. Andreas Diacon and colleagues investigate whether isoniazid is essential during the first 14 days of therapy and the inherent risk of including an ineffective drug in a combination regimen.

The breadth of topics in the journal related to tuberculosis emphasises that despite being an ancient disease there is still much to learn. It is dangerous to assume that efforts can entirely be directed elsewhere, even in response to the daunting challenges posed by COVID-19. We do not have the freedom to choose between one or the other. That some seem to think a choice must be made begs the questions: are the world\'s resources so inadequate that we must abandon progress made on tuberculosis to tackle the new challenge of COVID-19? Might a narrow approach concentrating on one disease ultimately prove more costly?

The Stop TB Partnership recently published modelling examining the potential impact of the COVID-19 response on tuberculosis in high-burden countries. They concluded that the disruption caused by the COVID-19 response will inevitably lead to an increase in morbidity and mortality in these settings, which will not return to pre-pandemic levels until at least 2025. There are the usual caveats associated with modelling; nonetheless, this is a plausible and conservative analysis. The predicted damage to tuberculosis control represents a 5--8-year setback and will require significant funding and, therefore, political will to be addressed. The response to the COVID-19 pandemic has shown that it is possible to summon this political will.

In their Correspondence in this issue, Rebecca Brown and Michael Head outline investments in coronavirus research and development. They explain that more than 40% of coronavirus research funding over the past 20 years was made available during this pandemic. Beyond research funding, nations have also found themselves more generally able to release funds in response to the current crisis. This fund mobilisation hints at something that is not really a surprise: there is money available to respond to crises should the need seem sufficiently urgent. But why does an infectious disease responsible for an average of 4000 deaths a day not warrant this urgency?

Somehow tuberculosis is not broadly seen as an urgent problem; given the international response to COVID-19, we know what an urgent response looks like. Now might not be the time to ramp up spending on tuberculosis as so many efforts are focussed elsewhere, but equally we must not be short-sighted and assume that a major infectious disease can be left to its own devices while we address a new priority. The problem here is not really about the understandably intense response to COVID-19, it is one of political will when it comes to major infectious diseases that need a long-term view. Although it is fair to criticise COVID-19 responses that seem to exclude all else, there is a wider issue here: why is tuberculosis, despite its unenviable status, so easily overlooked?

© 2020 Vivek Kapur2020Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
